volition.comRevolutionizing Cancer Diagnosis | Volition RX

Volition Menu Home Nu-Q ™ Press Room Press Releases Presentations & Posters Video Gallery Media Toolkit Investors Our expert team Our expert team Board of Directors Scientific Advisory Board Research team Contact Us Brighter tomorrow The dedicated team at Volition have a shared goal – to save lives by revolutionizing the way disease, and especially cancer, is diagnosed throughout the world. 2020 Volition Film Early diagnosis is key Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer. Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases. We believe that Nu.Q™ will provide a low-cost routine blood test allowing doctors to check off an extra box along with other routine blood tests, such as cholesterol and PSA, during a single visit, and that this is currently the only credible way of taking compliance with screening above 80%. Find out more “Early detection of cancer greatly increases the chances for successful treatment.” World Health Organization In the U.S. alone, three new cases of cancer are diagnosed every minute. The ongoing problem Cancer is the second leading cause of death worldwide with over 18.1 million new cases diagnosed each year. This causes over 9.6 million deaths worldwide and is expected to increase to over 16 million deaths by 2040. Current cancer diagnosis involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing. Dr. Jake Micallef, PhD, MBA CSO A simple test, with a small amount of blood. For more information on Nu.Q, click here Nu.Q runs on simple low-cost ELISA technology, which can utilize other tests for even higher accuracy. Rethinking the approach to cancer Nu.Q represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis . Intellectual Property Believed to be the only company working on ELISA measurement for epigenetically modified circulating nucleosomes. As of December 31, 2019: 23 Patent families 8 Patents granted in the U.S. 9 Patents granted in the E.U. 27 Additional patents granted worldwide 105 Patents pending Recent Videos Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies Play video 2020 Volition Corporate Film Play video Recent Press Releases 2020-04-23 Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies 2020-03-10 VolitionRx Limited Releases Annual Corporate Brochure and Video Company Update Brochure 2020 Open Contact Us Downloads Team Social Responsibility Privacy Policy Disclaimer Sign up to email alerts arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus ');...